Physician profile
Amit Nahata
NPI 1417928904
$29,974.93
in general payments reported to CMS, 2019-2025
28 companies · $617 in 2025
The $617 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $438 · 2020: $5,100 · 2021: $8,005 · 2022: $6,423 · 2023: $1,624 · 2024: $7,768 · 2025: $617.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $6,500 · Food and Beverage: $2,520 · Travel and Lodging: $722 · Consulting Fee: $240 · Education: $27.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $6,500.00 |
| Food and Beverage | $2,519.93 |
| Travel and Lodging | $721.71 |
| Consulting Fee | $240.00 |
| Education | $27.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $16,705.59 | 2019-2024 | Velphoro |
| Scpharmaceuticals INC. | $6,799.07 | 2024-2025 | |
| Novo Nordisk INC | $1,503.13 | 2022-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $569.68 | 2019-2024 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $504.70 | 2021-2025 | |
| Vifor (International) LTD. | $500.00 | 2020 | |
| Vifor Pharma, INC. | $442.37 | 2019-2025 | Veltassa |
| Glaxosmithkline, LLC. | $393.89 | 2022-2025 | Benlysta, Jesduvroq, Shingrix |
| Mallinckrodt Hospital Products INC. | $346.25 | 2021-2023 | Terlivaz, Acthar |
| Travere Therapeutics, INC. | $330.15 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $329.04 | 2019-2025 | Jynarque, Voyxact |
| Novartis Pharmaceuticals Corporation | $236.09 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $199.31 | 2023-2025 | Jardiance |
| Daiichi Sankyo INC. | $161.19 | 2021-2023 | Injectafer |
| Horizon Therapeutics Plc | $151.79 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $144.86 | 2022 | |
| Medtronic, INC. | $142.07 | 2023 | Endurant Iis |
| Opko Pharmaceuticals, LLC | $130.16 | 2022-2023 | Rayaldee |
| Lilly USA, LLC | $64.01 | 2023-2025 | Jardiance |
| Amgen INC. | $63.06 | 2019-2023 | Tavneos |
| Akebia Therapeutics INC | $60.88 | 2021-2025 | Vafseo |
| Ardelyx, INC. | $54.49 | 2024-2025 | Ibsrela |
| Calliditas Therapeutics US INC. | $43.79 | 2023 | Tarpeyo |
| Baxter Healthcare | $35.21 | 2021-2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $21.54 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $16.81 | 2022 | |
| Aurinia Pharma U.S., INC. | $14.93 | 2022 | |
| Mallinckrodt Enterprises LLC | $10.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amit Nahata listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.